证券研究报告 2025 年 06 月 18 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 3387.40 | -0.04 | | 深证成指 | 10151.43 | -0.12 | | 创业板指 | 2049.94 | -0.36 | | 科创 50 | 963.08 | -0.80 | | 北证 50 | 1402.54 | -0.40 | A 股市场概览 | 类别 | 总市值 | 流通市 | 市盈率 | 市净率 | | --- | --- | --- | --- | --- | | (亿元) | | 值(亿元) | PE | PB | | 上证指数 652616 | | 509901 | 12.03 | 1.25 | | 深证成指 224002 | | 183025 | 19.85 | 2.10 | | 创业板指 | 57948 | 45780 | 26.90 | 3.75 | | 科创 50 | 33565 | 22057 | 52.26 | 4.03 | | 北证 50 | 3210 | 2163 | 47.83 | 4 ...

Core Viewpoint - Xinhua Medical (600587) has received the Medical Device Registration Certificate from the Shandong Provincial Drug Administration for its Thromboelastography Activated Coagulation Testing Kit, indicating a significant advancement in its product offerings in the medical device sector [1] Company Summary - The product, Thromboelastography Activated Coagulation Testing Kit, is designed for in vitro detection of coagulation function in human whole blood samples [1] - The kit is applicable for conditions such as coagulation dysfunction, acute trauma, and shock, assisting doctors in evaluating coagulation status and determining the efficacy of pro-coagulant and anticoagulant medications [1] - The registration certificate number is Lu Xie Zhao Zhun 20252400309, with an approval date of June 4, 2025, and a validity period until June 3, 2030 [1] Industry Summary - The approval of this medical device highlights the growing importance of advanced diagnostic tools in the healthcare industry, particularly in managing coagulation disorders and preventing thrombosis [1]

证券代码：300030 证券简称：阳普医疗 真空采血管系统业务的行业领先地位。公司参与真空采血管、 血栓弹力图等产品的国家标准及行业标准制定与修订，是标准 主要起草人之一，积极推动行业进步和发展。自 2008 年起，公 司被认定为广东省进出口名牌企业、国家知识产权优势企业等； 2024 年两款产品获广东省名优高新技术产品。此外，公司在北 京、上海、广东等地区拥有大批代表性医院客户，具有广泛的 市场知名度及品牌影响力。公司的"阳普""阳普医疗"自主 品牌已成为国内临床医学检验实验室的著名品牌。 2、高管您好！请问贵公司本期财务报告中，盈利表现如何？ 谢谢！ 证券代码：300030 证券简称：阳普医疗 阳普医疗科技股份有限公司 投资者关系活动记录表 编号：20250429 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 业绩说明会 | | 活动类别 | □新闻发布会 路演活动 | | | □现场参观 | | □其他 | | | 参与单位名称 | 线上参与"公司 2024 年度网上业绩说明会"的投资者 | | 及人员姓名 | | | 时间 2025 | 年 ...